Literature DB >> 21186067

Synthesis and biological activity of novel inhibitors of topoisomerase I: 2-aryl-substituted 2-bis-1H-benzimidazoles.

Manish Singh1, Vibha Tandon.   

Abstract

Inhibitors of topoisomerase I constitute a novel family of antitumor agents. The class of benzimidazole derivatives contains compounds possessing affinity to DNA. For example, fluorescent stains Hoechst 33342 and Hoechst 33258 interact with DNA as ligand and produce nonspecific inhibition of the catalytic activity of many enzymes involved in DNA synthesis, including DNA topoisomerase and DNA helicase. Several 2-aryl-5-substituted-2,5-bisbenzimidazole derivatives were synthesized and ability of these derivatives to induce DNA cleavage in the presence of topoisomerase I was evaluated in vitro. These analogs were also assayed for their cytotoxicity against U87, MCF7 and HeLa human tumor cells. All the four compounds showed a potent growth inhibitory effect on all the cell lines, with IC50 in the μM range. Copyright Â
© 2010 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21186067     DOI: 10.1016/j.ejmech.2010.11.046

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  10 in total

1.  New Application of Neomycin B-Bisbenzimidazole Hybrids as Antifungal Agents.

Authors:  Nishad Thamban Chandrika; Sanjib K Shrestha; Nihar Ranjan; Anindra Sharma; Dev P Arya; Sylvie Garneau-Tsodikova
Journal:  ACS Infect Dis       Date:  2017-12-11       Impact factor: 5.084

2.  Synthesis and investigation of novel benzimidazole derivatives as antifungal agents.

Authors:  Nishad Thamban Chandrika; Sanjib K Shrestha; Huy X Ngo; Sylvie Garneau-Tsodikova
Journal:  Bioorg Med Chem       Date:  2016-06-04       Impact factor: 3.641

3.  The SARS-CoV-2 helicase as a target for antiviral therapy: Identification of potential small molecule inhibitors by in silico modelling.

Authors:  Eleni Pitsillou; Julia Liang; Andrew Hung; Tom C Karagiannis
Journal:  J Mol Graph Model       Date:  2022-04-18       Impact factor: 2.942

4.  3,4-dimethoxyphenyl bis-benzimidazole, a novel DNA topoisomerase inhibitor that preferentially targets Escherichia coli topoisomerase I.

Authors:  Sandhya Bansal; Devapriya Sinha; Manish Singh; Bokun Cheng; Yuk-Ching Tse-Dinh; Vibha Tandon
Journal:  J Antimicrob Chemother       Date:  2012-09-03       Impact factor: 5.790

5.  DMA, a bisbenzimidazole, offers radioprotection by promoting NFκB transactivation through NIK/IKK in human glioma cells.

Authors:  Navrinder Kaur; Atul Ranjan; Vinod Tiwari; Ritu Aneja; Vibha Tandon
Journal:  PLoS One       Date:  2012-06-22       Impact factor: 3.240

6.  Benzimidazole Schiff base derivatives: synthesis, characterization and antimicrobial activity.

Authors:  Thierry Youmbi Fonkui; Monisola Itohan Ikhile; Patrick Berka Njobeh; Derek Tantoh Ndinteh
Journal:  BMC Chem       Date:  2019-11-09

Review 7.  Importance of Fluorine in Benzazole Compounds.

Authors:  Thuraya Al-Harthy; Wajdi Zoghaib; Raid Abdel-Jalil
Journal:  Molecules       Date:  2020-10-14       Impact factor: 4.411

8.  Synthesis and Biological Evaluation of Novel 1H-Benzo[d]imidazole Derivatives as Potential Anticancer Agents Targeting Human Topoisomerase I.

Authors:  Stuti Pandey; Pragya Tripathi; Palak Parashar; Vikas Maurya; Md Zubbair Malik; Raja Singh; Pooja Yadav; Vibha Tandon
Journal:  ACS Omega       Date:  2022-01-10

9.  Synthesis and Antiproliferative Activities of Benzimidazole-Based Sulfide and Sulfoxide Derivatives.

Authors:  Samir T Gaballah; Ahmed O H El-Nezhawy; Hassan Amer; Mamdouh Moawad Ali; Abeer Essam El-Din Mahmoud; Andreas Hofinger-Horvath
Journal:  Sci Pharm       Date:  2015-08-18

10.  Synthesis and Anti-Proliferative Effects of Mono- and Bis-Purinomimetics Targeting Kinases.

Authors:  Andrea Bistrović; Anja Harej; Petra Grbčić; Mirela Sedić; Sandra Kraljević Pavelić; Mario Cetina; Silvana Raić-Malić
Journal:  Int J Mol Sci       Date:  2017-11-01       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.